CCBIO Seminar – Emily Arner
Welcome to a CCBIO seminar with Emily Arner from the Brekken lab at UT Southwestern Medical Center, Texas, and the Rathmell lab at Vanderbilt University Medical Center, Nashville. This is a digital event in Zoom, so you can participate from wherever your are. Open to the public.
Speaker: Emily Arner, the Brekken lab, UT Southwestern Medical Center, Texas / Rathmell lab at Vanderbilt University Medical Center, Nashville.
Dr. Emily Arner has received her PhD from UT Southwestern under the mentorship of Dr. Rolf Brekken and is a post-doctoral fellow in the lab of Dr. Kimryn Rathmell at Vanderbilt University Medical Center. Dr. Arner received an F99/K00 pre-doctoral to post-doctoral transition award from NCI. She is interested in cancer cell plasticity/metastasis and finding novel targets to inhibit this process.
Title: "AXL-TBK1 driven nuclear AKT3 stabilizes snail/slug to promote EMT"
Time: November 25 at 14.30 (timezone in Norway, 13:30 UK time, 08:30 Boston time, 07:30 Texas time)
Place: Digital event in a Zoom webinar. Link to join Webinar as audience: https://uib.zoom.us/j/61399295455?pwd=a3BHR2VBQUxjOFdLckRZbHpyL3I2UT09
If asked for a passcode, use this: 9ZEzecdq
Host: Jim Lorens
Abstract: Epithelial-to-mesenchymal transition (EMT) contributes to tumor cell survival, immune evasion, migration, invasion, and therapy resistance. Across human cancer, tumors that are high grade, poorly differentiated, and have undergone EMT carry a worse prognosis with a higher likelihood of metastasis. AXL, a receptor tyrosine kinase, drives EMT and is implicated in tumor progression, metastasis, and therapy resistance in multiple cancer types including pancreatic cancer and breast cancer. TANK-binding kinase 1 (TBK1) is central to AXL-driven EMT yet, the mechanism of how TBK1 induces EMT remains unclear. Here, we report that AXL activation stimulates TBK1 binding and phosphorylation of AKT3. TBK1 activation of AKT3 drives binding to slug/snail, protection of snail/slug from proteasomal degradation and translocation of the complex to the nucleus. We show that nuclear translocation of AKT3 is required for AXL-driven EMT and metastasis. Congruently, nuclear AKT3 expression correlates with worse outcome in aggressive breast cancer. These results suggest that AKT3 nuclear activity is an important feature of AXL-driven epithelial plasticity and that selective AKT3 inhibition represents a novel therapeutic avenue for treating aggressive cancer.
Note: Please change any username to your name when logging in, so that chair can address you by name if you have questions.
- Your sound and video will be turned off as default for security reasons, and only host can de-mute individual participants.
- We will open for questions after the lecture, where you can use the Raise hand function, or type your question in Chat. Host will then de-mute your sound and address you by your name (please log on with your name).
- If you think you might want to ask questions, please test your microphone beforehand. Make sure your microphone is turned on. (Or ask host to read out your typed question).
- We advise all to have a Zoom account on your device beforehand (free service), that will save you some minutes when logging on.
Those of us with University of Bergen (UiB) client machines, might already have Zoom. If not, see https://it.uib.no/Jeg_skal_bruke_Zoom_for_f%C3%B8rste_gangFor private machines (not UiB), see https://zoom.us/download#client_4meeting Otherwise, clicking the logon link provided above will prompt the Zoom app to download, but it saves you time to have done this beforehand.